Compare · MRNA vs ODT
MRNA vs ODT
Side-by-side comparison of Moderna Inc. (MRNA) and Odonate Therapeutics Inc. (ODT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and ODT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $90.38B.
- MRNA has hit the wire 14 times in the past 4 weeks while ODT has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for ODT).
- Company
- Moderna Inc.
- Odonate Therapeutics Inc.
- Price
- -
- -
- Market cap
- $90.38B
- -
- 1M return
- -5.59%
- -
- 1Y return
- +801.53%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2017
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 0
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Odonate Therapeutics Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
Latest ODT
- SEC Form 25-NSE filed by Odonate Therapeutics Inc.
- 60 Biggest Movers From Yesterday
- 56 Biggest Movers From Friday
- Odonate Therapeutics shares are trading lower after the company received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Stocks That Hit 52-Week Lows On Friday
- Odonate Therapeutics Announces Expected Delisting Of Stock
- Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Odonate Announces Expected Delisting of Its Stock
- Stocks That Hit 52-Week Lows On Thursday